| Citation: |
ZHU Xiaoli, XU Lu. Research Progress of Markers Related to Early Diagnosis of Lung Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(9): 875-879. DOI: 10.3971/j.issn.1000-8578.2022.21.1483
|
Lung cancer is the cancer with the highest mortality in China. Early detection and early diagnosis are the key factors affecting the therapeutic effect of lung cancer treatment. However, accurate and safe early diagnosis methods for lung cancer are still lacking, greatly affecting the survival of lung cancer patients. Lung cancer, as a highly malignant tumor, has attracted the attention of scientists to study its diagnostic biomarkers. These diagnostic biomarkers are diverse, but their value in the early diagnosis of lung cancer remains to be further explored. In this paper, the biomarkers related to the early diagnosis of lung cancer are sorted out, and the latest progress, potential value, advantages, and limitations of these biomarkers in lung cancer diagnosis are reviewed.
Competing interests: The authors declare that they have no competing interests.
| [1] |
Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. doi: 10.3322/caac.21660
|
| [2] |
Goldstraw P, Chansky K, Crowley J, et al. The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer[J]. J Thorac Oncol, 2016, 11(1): 39-51. doi: 10.1016/j.jtho.2015.09.009
|
| [3] |
Yan HJ, Ma JY, Wang L, et al. Expression and significance of circulating microRNA-31 in lung cancer patients[J]. Med Sci Monit, 2015, 21: 722-726. doi: 10.12659/MSM.893213
|
| [4] |
Zhao K, Cheng J, Chen B, et al. Circulating microRNA-34 family low expression correlates with poor prognosis in patients with non-small cell lung cancer[J]. J Thorac Dis, 2017, 9(10): 3735-3746. doi: 10.21037/jtd.2017.09.01
|
| [5] |
Powrózek T, Krawczyk P, Kowalski DM, et al. Plasma circulating microRNA-944 and microRNA-3662 as potential histologic type-specific early lung cancer biomarkers[J]. Transl Res, 2015, 166(4): 315-323. doi: 10.1016/j.trsl.2015.05.009
|
| [6] |
Yan W, Xu T, Zhu H, et al. Clinical Applications of Cerebrospinal Fluid Circulating Tumor DNA as a Liquid Biopsy for Central Nervous System Tumors[J]. Onco Targets Ther, 2020, 13: 719-731. doi: 10.2147/OTT.S229562
|
| [7] |
Avanzini S, Kurtz DM, Chabon JJ, et al. A mathematical model of ctDNA shedding predicts tumor detection size[J]. Sci Adv, 2020, 6(50): eabc4308. doi: 10.1126/sciadv.abc4308
|
| [8] |
Sueoka-Aragane N, Nakashima C, Yoshida H, et al. The role of comprehensive analysis with circulating tumor DNA in advanced non-small cell lung cancer patients considered for osimertinib treatment[J]. Cancer Med, 2021, 10(12): 3873-3885. doi: 10.1002/cam4.3929
|
| [9] |
Peng M, Xie Y, Li X, et al. Resectable lung lesions malignancy assessment and cancer detection by ultra-deep sequencing of targeted gene mutations in plasma cell-free DNA[J]. J Med Genet, 2019, 56(10): 647-653. doi: 10.1136/jmedgenet-2018-105825
|
| [10] |
Cohen JD, Li L, Wang Y, et al. Detection and localization of surgically resectable cancers with a multi-analyte blood test[J]. Science, 2018, 359(6378): 926-930. doi: 10.1126/science.aar3247
|
| [11] |
Gassa A, Fassunke J, Schueten S, et al. Detection of circulating tumor DNA by digital droplet PCR in resectable lung cancer as a predictive tool for recurrence[J]. Lung Cancer, 2021, 151: 91-96. doi: 10.1016/j.lungcan.2020.10.019
|
| [12] |
Soria-Comes T, Palomar-Abril V, Ureste MM, et al. Real-World Data of the Correlation between EGFR Determination by Liquid Biopsy in Non-squamous Non-small Cell Lung Cancer (NSCLC) and the EGFR Profile in Tumor Biopsy[J]. Pathol Oncol Res, 2020, 26(2): 845-851. doi: 10.1007/s12253-019-00628-x
|
| [13] |
Campos-Carrillo A, Weitzel JN, Sahoo P, et al. Circulating tumor DNA as an early cancer detection tool[J]. Pharmacol Ther, 2020, 207: 107458. doi: 10.1016/j.pharmthera.2019.107458
|
| [14] |
Ehrlich M. DNA hypomethylation in cancer cells[J]. Epigenomics, 2009, 1(2): 239-259. doi: 10.2217/epi.09.33
|
| [15] |
Esteller M, Sanchez-Cespedes M, Rosell R, et al. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients[J]. Cancer Res, 1999, 59(1): 67-70.
|
| [16] |
Ooki A, Maleki Z, Tsay JJ, et al. A Panel of Novel Detection and Prognostic Methylated DNA Markers in Primary Non-Small Cell Lung Cancer and Serum DNA[J]. Clin Cancer Res, 2017, 23(22): 7141-7152. doi: 10.1158/1078-0432.CCR-17-1222
|
| [17] |
Hulbert A, Jusue-Torres I, Stark A, et al. Early Detection of Lung Cancer Using DNA Promoter Hypermethylation in Plasma and Sputum[J]. Clin Cancer Res, 2017, 23(8): 1998-2005. doi: 10.1158/1078-0432.CCR-16-1371
|
| [18] |
Jurkowska RZ, Jeltsch A. Enzymology of Mammalian DNA Methyltransferases[J]. Adv Exp Med Biol, 2016, 945: 87-122.
|
| [19] |
Massion PP, Healey GF, Peek LJ, et al. Autoantibody Signature Enhances the Positive Predictive Power of Computed Tomography and Nodule-Based Risk Models for Detection of Lung Cancer[J]. J Thorac Oncol, 2017, 12(3): 578-584. doi: 10.1016/j.jtho.2016.08.143
|
| [20] |
Jett JR, Peek LJ, Fredericks L, et al. Audit of the autoantibody test, EarlyCDT®-lung, in 1600 patients: an evaluation of its performance in routine clinical practice[J]. Lung Cancer, 2014, 83(1): 51-55. doi: 10.1016/j.lungcan.2013.10.008
|
| [21] |
Ren S, Zhang S, Jiang T, et al. Early detection of lung cancer by using an autoantibody panel in Chinese population[J]. Oncoimmunology, 2018, 7(2): e1384108. doi: 10.1080/2162402X.2017.1384108
|
| [22] |
He Y, Shi J, Schmidt B, et al. Circulating Tumor Cells as a Biomarker to Assist Molecular Diagnosis for Early Stage Non-Small Cell Lung Cancer[J]. Cancer Manag Res, 2020, 12: 841-854. doi: 10.2147/CMAR.S240773
|
| [23] |
Ding C, Zhou X, Xu C, et al. Circulating tumor cell levels and carcinoembryonic antigen: An improved diagnostic method for lung adenocarcinoma[J]. Thorac Cancer, 2018, 9(11): 1413-1420. doi: 10.1111/1759-7714.12851
|
| [24] |
Lv X, Wu S, Xu X, et al. The combination of folate receptor-positive circulating tumor cells and serum tumor markers suggests a histological diagnosis of lung cancer[J]. J Thorac Dis, 2022, 14(1): 158-168. doi: 10.21037/jtd-21-1975
|
| [25] |
Wan L, Liu Q, Liang D, et al. Circulating Tumor Cell and Metabolites as Novel Biomarkers for Early-Stage Lung Cancer Diagnosis[J]. Front Oncol, 2021, 11: 630672. doi: 10.3389/fonc.2021.630672
|
| [26] |
Ye M, Tong L, Zheng X, et al. A Classifier for Improving Early Lung Cancer Diagnosis Incorporating Artificial Intelligence and Liquid Biopsy[J]. Front Oncol, 2022, 12: 853801. doi: 10.3389/fonc.2022.853801
|
| [27] |
Duan GC, Zhang XP, Wang HE, et al. Circulating Tumor Cells as a Screening and Diagnostic Marker for Early-Stage Non-Small Cell Lung Cancer[J]. Onco Targets Ther, 2020, 13: 1931-1939. doi: 10.2147/OTT.S241956
|
| [28] |
Kang BJ, Ra SW, Lee K, et al. Circulating Tumor Cell Number Is Associated with Primary Tumor Volume in Patients with Lung Adenocarcinoma[J]. Tuberc Respir Dis(Seoul), 2020, 83(1): 61-70. doi: 10.4046/trd.2019.0048
|
| [29] |
Yao H, Wang Z, Yang J, et al. Simultaneous in situ detection of protein expression of multiple tumor markers of circulating tumor cells and heteroploid of chromosome 8 in primary lung cancer[J]. Ann Transl Med, 2021, 9(24): 1772. doi: 10.21037/atm-21-6346
|
| [30] |
Shaffie A, Soliman A, Fu XA, et al. A novel technology to integrate imaging and clinical markers for non-invasive diagnosis of lung cancer[J]. Sci Rep, 2021, 11(1): 4597. doi: 10.1038/s41598-021-83907-5
|
| [31] |
Xie Y, Meng WY, Li RZ, et al. Early lung cancer diagnostic biomarker discovery by machine learning methods[J]. Transl Oncol, 2021, 14(1): 100907. doi: 10.1016/j.tranon.2020.100907
|
This work is licensed under a Creative Commons Attribution 3.0 License.
Copyright © Editorial Department of Cancer Prevention Research 鄂公网安备 42011102005013号 鄂ICP备2022015867号
Supported by: Beijing Renhe Information Technology Co., Ltd. 
DownLoad: